Opportunity ID: 276387

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-15-NFRP-NIA
Funding Opportunity Title: DoD Neurofibromatosis New Investigator Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 4
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: May 06, 2015
Last Updated Date:
Original Closing Date for Applications: Jul 27, 2015
Current Closing Date for Applications: Jul 27, 2015
Archive Date: Aug 26, 2015
Estimated Total Program Funding: $2,880,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description: The intent of the NFRP New Investigator Award is to support the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in the field of NF research. Prior experience in NF research is not required. However, Principal Investigators (PIs) with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field.
Research projects may focus on any phase of research, excluding clinical trials. Applications must include preliminary and/or published data that is relevant to NF and the proposed research project.
Preclinical Research: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al. A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in research and should be applied. For projects involving animal studies, applicants should consult the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines can be found at http://www.nc3rs.org.uk/page.asp?id=1357.
Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email:help@eBRAP.org

Version History

Version Modification Description Updated Date

Folder 276387 Full Announcement-1 -> nfrp_fy15_nia eligibility statement_gg.pdf

Folder 276387 Full Announcement-1 -> nfrp_fy15_nia_pa_gg.pdf

Packages

Agency Contact Information: CDMRP Help Desk
Phone: 301-682-5507

Email: help@eBRAP.org

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00216698 May 06, 2015 Jul 27, 2015 View

Package 1

Mandatory forms

276387 RR_SF424_2_0-2.0.pdf

276387 RR_Budget_1_3-1.3.pdf

276387 RR_KeyPersonExpanded_2_0-2.0.pdf

276387 PerformanceSite_2_0-2.0.pdf

Optional forms

276387 RR_SubawardBudget30_1_3-1.3.pdf

2025-07-01T06:42:48-05:00

Share This Post, Choose Your Platform!

About the Author: